Why Three Drug-Development Routes All Validate Through IL-12 R beta 1: From p40 and p19 to the Receptor Side
p40 blockers, p19-selective IL-23 inhibitors and receptor-side programs all converge on IL-12Rβ1 engagement assays. This article traces the validation chain.
- Recent Advances
- Product Information
Recent Advances
Abstract: p40 blockers, p19-selective IL-23 inhibitors and receptor-side programs all converge on IL-12Rβ1 engagement assays. This article traces the validation chain.
Keywords: IL-12 R beta 1, IL-23, p40, p19, drug development, target validation, UA010373
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
Product Information






